Anti-PDL1 Immunotherapy as a Radiosensitizer on Treating Advanced Recurrent Oropharyngeal Squamous Cell Carcinoma

Ear Nose Throat J. 2021 Sep;100(5_suppl):415S-416S. doi: 10.1177/0145561319881565. Epub 2019 Nov 6.

Authors

Yi-An Pan¹, Nai-Wen Su^{2

3

4}, Yi-Shing Leu^{1

2}

Affiliations

¹ Department of Otolaryngology-Head and Neck Surgery, Mackay Memorial Hospital, Taipei.
² School of Medicine, Mackay Medical College, New Taipei City.
³ Division of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei.
⁴ Department of Medical Research, Laboratory of Good Clinical Research Center, MacKay Memorial Hospital, Tamsui District, New Taipei City.

PMID: 31690109
DOI: 10.1177/0145561319881565

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antineoplastic Agents, Immunological / administration & dosage*
B7-H1 Antigen / immunology
Chemoradiotherapy / methods
Dose Fractionation, Radiation
Humans
Male
Medical Illustration
Middle Aged
Neoplasm Recurrence, Local / therapy*
Oropharyngeal Neoplasms / therapy*
Squamous Cell Carcinoma of Head and Neck / therapy*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
durvalumab